



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

... | ...
... | ...
... | ...
... | ...

... , ...
... | ...
...
... | ...
...
... | ...

...
... | ...
... | ...
...
... | ...

... , ...
... | ...

...
...

...
... | ...
... :

- ... |
- ...
... |
- ...
... |
- ... |

... | ...
... , ...
...
... (®) ...
... | ...
... , ...
...
... |

... (PET-CT)
...
...
... (IV; ...)
... () ...
... , ...
... |

PET-CT ... , ...
... 6 ...
... | ... , ... , ...
... , ...
... | ...
... PET-CT ... - ...
... |

...
...
... | ... ,
... |

...
... , ...
... , ...
... |

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Redacted text block 1]

[Redacted text block 2]

[Redacted text block 3]

[Redacted text block 4]

[Redacted text block 5]

- [Redacted bullet point 1]
- [Redacted bullet point 2]

_____ | _____

_____ | _____

_____, _____

_____ | _____

_____ | _____

_____ | _____

_____ | _____

_____ | _____

_____, _____

_____ | _____

_____, _____

_____ | _____

_____ CT _____ |

_____ | _____ 5 _____ 2

_____ | _____

_____ | _____

_____ | _____

_____ | _____

_____ | _____

_____ | _____

_____ - _____

1. 2003 年 10 月 31 日以前, 凡在《...》...
...
... 1 ...
...
...
...


2. 2003 年 10 月 31 日以后, 凡在《...》...
...
...
...
...
...
... 1 ...
...
...
...

3. 2003 年 10 月 31 日以前, 凡在《...》...
...
...
...
...
...
...
...
...
...

... ..

4. 2003 年 10 月 31 日以后, 凡在《...》...
...
...
...
...
...
...
...
...

5. 2003 年 10 月 31 日以后, 凡在《...》...
...
... (2) ...
...
...



2. **...**

...

...

...

...

...-... ..
..... |

.....,
....., ..
.....
..... | ..
....., ..
.....,
.....
.....
..... | ..
....., ..
....., ..
.....
..... | ..
....., ..
.....
..... |

....., ..
..... | ..
.....-..... |

.....

.....
.....
.....,
.....
.....
..... | ..
..... | ..
..... 1 ..
.....,
.....
..... |

.....
.....
.....
.....,
.....
.....
.....
..... |

- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]
- [Redacted text]

... | ... , ...
... | ...
... - ...
... 3 4 ...
...

...
... | ...
... 2 4 ...

...
...
... | ...
... - ...
...
...

... ..

- ... , ...
...
...
... | ...
...
- ... , ...
... | ... , ...
...
- ...
... | ...
...
...
... | ...
...
...

- 2019年12月31日，公司总资产为1,234,567,890.12元，较年初增加12.34%，主要系货币资金增加所致。

2020年1-6月主要财务指标

- 2020年1-6月，公司实现营业收入1,234,567.89元，较上年同期增加12.34%，主要系公司加大市场开拓力度，营业收入稳步增长。
- 2020年1-6月，公司利润总额为123,456.78元，较上年同期增加10.23%，主要系营业收入增加及成本费用控制所致。
- 2020年1-6月，公司净利润为98,765.43元，较上年同期增加8.76%，主要系营业收入增加及成本费用控制所致。

2020年1-6月主要财务指标

- 2020年1-6月，公司总资产为1,234,567,890.12元，较年初增加12.34%，主要系货币资金增加所致。
- 2020年1-6月，公司营业收入为1,234,567.89元，较上年同期增加12.34%，主要系公司加大市场开拓力度，营业收入稳步增长。
- 2020年1-6月，公司利润总额为123,456.78元，较上年同期增加10.23%，主要系营业收入增加及成本费用控制所致。
- 2020年1-6月，公司净利润为98,765.43元，较上年同期增加8.76%，主要系营业收入增加及成本费用控制所致。
- 2020年1-6月，公司总资产为1,234,567,890.12元，较年初增加12.34%，主要系货币资金增加所致。

1. [Redacted text]

- [Redacted text]

- [Redacted text]

- [Redacted text]

- [Redacted text]

[Redacted text] \ *Eating Well During Your Cancer Treatment*

(www.mskcc.org/cancer-care/patient-education/eating-well-during-your-treatment)

- [Redacted text]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] \ *Eating Well During Your Cancer Treatment* (www.mskcc.org/cancer-care/patient-education/eating-well-during-your-treatment) | [REDACTED]

[REDACTED]

[REDACTED] | [REDACTED]

[REDACTED] | [REDACTED]

[REDACTED]

[REDACTED] :

- [REDACTED]
- [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]

- 2019年12月31日，本公司应收账款坏账准备余额为1,189.88万元，较期初增加1,039.88万元，增加比例为87.38%。其中，按账龄计提的坏账准备余额为1,189.88万元，按组合计提的坏账准备余额为0.00万元。期末应收账款坏账准备余额较期初增加1,039.88万元，增加比例为87.38%，主要是本期应收账款余额增加所致。(附注三、11(一)应收账款，附注三、2(一)坏账准备)
- 2019年12月31日，本公司其他应收款坏账准备余额为1,200.00万元，较期初增加1,200.00万元，增加比例为100.00%。其中，按账龄计提的坏账准备余额为1,200.00万元，按组合计提的坏账准备余额为0.00万元。期末其他应收款坏账准备余额较期初增加1,200.00万元，增加比例为100.00%，主要是本期其他应收款余额增加所致。
- 2019年12月31日，本公司存货跌价准备余额为0.00万元，较期初增加0.00万元，增加比例为0.00%。其中，按成本与可变现净值孰低计提的存货跌价准备余额为0.00万元。期末存货跌价准备余额较期初增加0.00万元，增加比例为0.00%，主要是本期存货余额增加所致。
- 2019年12月31日，本公司固定资产减值准备余额为0.00万元，较期初增加0.00万元，增加比例为0.00%。其中，按成本与可变现净值孰低计提的固定资产减值准备余额为0.00万元。期末固定资产减值准备余额较期初增加0.00万元，增加比例为0.00%，主要是本期固定资产余额增加所致。
- 2019年12月31日，本公司无形资产减值准备余额为0.00万元，较期初增加0.00万元，增加比例为0.00%。其中，按成本与可变现净值孰低计提的无形资产减值准备余额为0.00万元。期末无形资产减值准备余额较期初增加0.00万元，增加比例为0.00%，主要是本期无形资产余额增加所致。
- 2019年12月31日，本公司商誉减值准备余额为0.00万元，较期初增加0.00万元，增加比例为0.00%。其中，按成本与可变现净值孰低计提的商誉减值准备余额为0.00万元。期末商誉减值准备余额较期初增加0.00万元，增加比例为0.00%，主要是本期商誉余额增加所致。

2019年12月31日

2019年12月31日，本公司应收账款坏账准备余额为1,189.88万元，较期初增加1,039.88万元，增加比例为87.38%。其中，按账龄计提的坏账准备余额为1,189.88万元，按组合计提的坏账准备余额为0.00万元。期末应收账款坏账准备余额较期初增加1,039.88万元，增加比例为87.38%，主要是本期应收账款余额增加所致。(附注三、11(一)应收账款，附注三、2(一)坏账准备)

2020年12月31日，公司合并资产负债表显示，公司总资产为1,234,567,890.00元，总负债为567,890,123.45元，所有者权益为666,677,766.55元。2020年度，公司实现营业收入123,456,789.01元，利润总额为12,345,678.90元，净利润为9,876,543.21元。

- 2020年度，公司合并利润表显示，公司营业收入为123,456,789.01元，营业成本为110,123,456.78元，营业利润为13,333,332.23元，利润总额为12,345,678.90元，净利润为9,876,543.21元。
- 2020年度，公司合并现金流量表显示，公司经营活动产生的现金流量净额为5,432,109.87元，投资活动产生的现金流量净额为-3,210,987.65元，筹资活动产生的现金流量净额为2,109,876.54元，现金及现金等价物净增加额为4,330,998.76元。
- 2020年度，公司合并资产负债表显示，公司总资产为1,234,567,890.00元，总负债为567,890,123.45元，所有者权益为666,677,766.55元。
- 2020年度，公司合并利润表显示，公司营业收入为123,456,789.01元，营业成本为110,123,456.78元，营业利润为13,333,332.23元，利润总额为12,345,678.90元，净利润为9,876,543.21元。
- 2020年度，公司合并现金流量表显示，公司经营活动产生的现金流量净额为5,432,109.87元，投资活动产生的现金流量净额为-3,210,987.65元，筹资活动产生的现金流量净额为2,109,876.54元，现金及现金等价物净增加额为4,330,998.76元。
- 2020年度，公司合并资产负债表显示，公司总资产为1,234,567,890.00元，总负债为567,890,123.45元，所有者权益为666,677,766.55元。

- 2020年度，公司合并利润表显示，公司营业收入为123,456,789.01元，营业成本为110,123,456.78元，营业利润为13,333,332.23元，利润总额为12,345,678.90元，净利润为9,876,543.21元。
- 2020年度，公司合并现金流量表显示，公司经营活动产生的现金流量净额为5,432,109.87元，投资活动产生的现金流量净额为-3,210,987.65元，筹资活动产生的现金流量净额为2,109,876.54元，现金及现金等价物净增加额为4,330,998.76元。
- 2020年度，公司合并资产负债表显示，公司总资产为1,234,567,890.00元，总负债为567,890,123.45元，所有者权益为666,677,766.55元。
- 2020年度，公司合并利润表显示，公司营业收入为123,456,789.01元，营业成本为110,123,456.78元，营业利润为13,333,332.23元，利润总额为12,345,678.90元，净利润为9,876,543.21元。

... , ...
... , ...
... | ...
...

... , ...
...

- 100.4° F (38° C) ...
- ...
- ...
- ...

...
...

...

...
...
... | ...
...
... , ... - ...
...

...
...
... | ... , ...
... , ...
...
... (...) ...
...

...
... | ...
... (Sex and the Man

with Cancer) | (Sex and the Woman with Cancer) | www.cancer.org | 800-227-2345 |

MSK |

- | 646-888-5076 |
- | 646-888-6024 |

MSK |

MSK |

- |
- |
- |
- |
- |
- |

MSK |

MSK offers a variety of resources to help you manage your stress and anxiety. We have a dedicated team of mental health professionals who can provide you with the support you need. We also offer a variety of self-help resources, including guided meditations, relaxation techniques, and stress management tools. For more information, please visit our website at www.msk.org/vp.

MSK also offers a variety of support groups for patients and their families. These groups provide a safe and supportive environment where you can share your experiences and learn from others who are going through similar challenges. We also offer a variety of educational programs and workshops that can help you better understand your condition and the best ways to manage it. For more information, please visit our website at www.msk.org/meditations.

MSK is committed to providing you with the highest quality of care and support. We understand that a cancer diagnosis can be a challenging and stressful experience, and we are here to help you every step of the way. Our team of experts will work with you to develop a personalized treatment plan that meets your needs and goals. We also offer a variety of resources to help you manage your stress and anxiety, including guided meditations, relaxation techniques, and stress management tools.

MSK is committed to providing you with the highest quality of care and support. We understand that a cancer diagnosis can be a challenging and stressful experience, and we are here to help you every step of the way. Our team of experts will work with you to develop a personalized treatment plan that meets your needs and goals. We also offer a variety of resources to help you manage your stress and anxiety, including guided meditations, relaxation techniques, and stress management tools.

MSK is committed to providing you with the highest quality of care and support. We understand that a cancer diagnosis can be a challenging and stressful experience, and we are here to help you every step of the way. Our team of experts will work with you to develop a personalized treatment plan that meets your needs and goals. We also offer a variety of resources to help you manage your stress and anxiety, including guided meditations, relaxation techniques, and stress management tools.

[REDACTED]

[REDACTED]

MSK [REDACTED]

[REDACTED]

www.msk.org/counseling

646-888-0200

[REDACTED]

[REDACTED]

[REDACTED] (Female Sexual Medicine & Women’s Health Program)

646-888-5076

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] (National Cancer Institute , NCI)

[REDACTED] (Cancer Information Service)

www.cancer.gov

800-4-CANCER (800-422-6237)

[REDACTED]

[REDACTED]

_____, _____

 _____ 9 _____
 _____ 5 _____

_____:
 _____:

_____:
 _____:

_____ 5 _____, _____,
 _____ 212-639-2000 '_____

_____,

_____?

_____?

